Skip to main content

LIVE

BVS

Bioventus Inc.

BVS

NASDAQ·Healthcare·Medical - Devices·Mkt cap $953.2M

$14.07

-2.02%

P/E

17.76

Mkt Cap

$953.2M

52-Wk Range

$6.26–$15.89

52-Week Range

$6.26 - $15.89

P/E

17.76

Fwd P/E

18.11

Beta

0.65

Div Yield

0.00%

Avg Vol

697.4K

Shares Out

67.4M

Mkt Cap

$953.2M

Price action

Price chart

Up 95.2% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Comprehensive product portfolio spanning the entire orthopedic continuum from pain management to surgical and restorative solutions
  • Proprietary ultrasonic and regenerative technology platforms that enhance natural healing processes
  • Established relationships with orthopedic specialists across multiple surgical disciplines and care settings
  • Focus on minimally invasive alternatives addressing the market shift away from traditional surgical approaches

Bear Case

1 risk

  • Low volatility (beta 0.7).

Growth

Stable outlook

Aging global population driving increased orthopedic procedures and chronic pain management demand

Value

Fairly valued vs Medical Devices peers

Momentum

Hot

+57.2% over 3m

Quality

Excellent

Excellent business quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 3, 2026

Q3 26 RECAP

AUG 5, 2026

Reported EPS of $0.22 vs $0.22 consensus (+1.7% surprise). Revenue of $153.2M vs $155.4M expected (-1.4%).

EPS beat +1.7%
Revenue miss

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+1.7%

Revenue trend · last 8Q

+13%

-4%

-2%

-0%

+3%

+7%

+4%

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$139.0M

$153.6M

$123.9M

$147.7M

$138.7M

$157.9M

$132.1M

$153.2M

Margins · last 8Q

Gross

69.0%

Operating

12.5%

Profit

21.8%

Wall Street consensus

2 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

2

100%

Hold

0%

Sell

0%

Median Price Target

Latest: Craig-Hallum · Aug 6, 2026

vs Industry

How BVS stacks vs Medical - Devices

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.